Artiva Biotherapeutics, Inc. ARTV PHARMA
Company Overview
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +307.49% |
| 6 Months: | +90.54% |
| 3 Months: | +60.00% |
| 1 Month: | -3.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)46.64 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ARTV Artiva Biotherapeutics, Inc. PHARMA | 10.88 | -3.37 | $531.92M | 0.00% | -76.21% | -36.58% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 3.50M | 26.66M | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | 22.17M | 22.81M | 22.90M | 21.93M | 24.43M | - |
| Operating Income | - | -11.82M | 10.81M | -14.49M | -16.19M | -18.34M | - | -22.17M | -22.81M | -22.90M | -21.93M | -24.43M | -26.89M |
| EBITDA | - | - | - | - | - | - | - | -21.54M | -22.17M | -22.23M | -21.27M | -23.76M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | -20.31M | -21.25M | -21.53M | -20.77M | -23.52M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -16.72M | -11.28M | 11.28M | -13.96M | -17.84M | -17.47M | - | -20.31M | -21.25M | -21.53M | -20.77M | -23.52M | -25.00M |
| Diluted EPS | - | -14.09 | 1.62 | -17.24 | -22.00 | -0.92 | - | -0.83 | -0.87 | -0.88 | - | -0.95 | -0.63 |
| R&D Expense | - | 11.26M | 13.06M | 11.16M | 12.33M | 13.52M | - | 17.05M | 17.86M | 17.63M | - | 19.31M | 21.93M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 32.92M | 251.00K | 0 |
| Operating Income | -30.67M | -67.28M | -89.81M |
| Net Income | -28.72M | -65.37M | -83.86M |
| Diluted EPS | -35.78 | -5.81 | -3.43 |
| R&D Expense | 50.25M | 50.33M | 69.54M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 133.05M | 105.11M | 209.58M | 130.94M |
| Current Assets | - | 104.67M | 79.82M | 188.63M | 112.67M |
| Cash & Equivalents | - | 102.53M | 53.50M | 40.23M | 26.70M |
| Inventory | - | - | - | - | - |
| Receivables | 468.00K | 525.00K | 1.03M | 0 | - |
| Total Liabilities | - | 273.75M | 267.13M | 22.94M | 20.97M |
| Current Liabilities | - | 25.62M | 12.23M | 12.25M | 13.09M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 19.45M | 16.91M | 14.35M | 10.94M |
| Total Equity | - | -140.70M | -162.01M | 186.64M | 109.97M |
| Shares Outstanding | - | 23.28M | 23.28M | 24.29M | 24.60M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -47.43M | -55.03M | -76.75M |
| Investing Cash Flow | -25.98M | -120.46M | 63.41M |
| Financing Cash Flow | 24.39M | 162.23M | 9.00K |
| Capital Expenditure | -3.26M | -642.00K | -2.59M |
| Free Cash Flow | -50.69M | -55.67M | -79.34M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | -93.2% | -26,805.6% | - |
| Net Margin % | -87.2% | -26,045.0% | - |
| ROE % | 17.7% | -35.0% | -76.3% |
| ROCE % | -33.0% | -34.1% | -76.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 36.73% | 17.96M | $154.60M |
| 2 | Viking Global Investors, L.P. | 5.33% | 2.60M | $22.42M |
| 3 | Blackstone Inc | 4.92% | 2.40M | $20.69M |
| 4 | 5AM Venture Management, LLC | 4.81% | 2.35M | $20.26M |
| 5 | Venrock Adviser, LLC | 4.18% | 2.04M | $17.60M |
| 6 | Franklin Resources, Inc. | 4.09% | 2.00M | $17.20M |
| 7 | Caligan Partners, LP | 3.55% | 1.74M | $14.95M |
| 8 | Vanguard Capital Management LLC | 2.01% | 981.82K | $8.45M |
| 9 | Samsara BioCapital, LLC | 1.95% | 954.86K | $8.22M |
| 10 | Blue Owl Capital Holdings LP | 1.79% | 874.54K | $7.53M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ARTV
ARTV Stock Price and Chart — NASDAQ:ARTV - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE9zTks0M29OLXF2VG10VG1odzUyaGFhenFmdkRxTENvSER4SlNfTktoOHd5bVk1VndvMjVBNnNVSF9UX19DX19STWJ6R01acjMwMDZYWUdWRU5PUXBY?oc=5" target="_blank">ARTV Stock Price and Chart — NASDAQ:ARTV</a…
How (ARTV) Movements Inform Risk Allocation Models - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPN0piX2ZhSlB6U0FTcnRNY1ZxVXNCVXcwQl9ZLWlIb3E3WVZZNXd2MzZiRlFNWmMyeWJXRGwzbzBwdnE1eExycVEybFFhbnVhN0tHSl84NFFCZUJDNHhRdWxtMkpDcmgxZTF4enppZFd3aUVLQTZtNkttZTZOYWxaU2FKeEJCZWpOYlRBdF…
Have Insiders Sold Artiva Biotherapeutics Shares Recently? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxPUVA4VGtjUEFYWi1fTmY1dHFDcC1WR3lFQ2lsRGxQRzRPTExzbk5ZcmFNeVF0VU1nU2NTek9nNWFQVWI4OTI0cFZOMGF6STFTc0NpWTF6dllYVE1ueW04a29YRkdKeUl2cDdINmJFS0hTNlNvaXp3YzByb0FmM3AtTnp5ekRzVXdiT1JOdl…
Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQT1RvTmJ6bUtZTzdndWctZ1BjclZXUVVRak8wTUQxSWFKSHRHTGF5LXBYUXB0bEVVZ1ZBNVZjWWxaSWVQa2IxZTlSbl9iZHRJel9nRkFjR3cyZU4wREViQldxbk1UU0paWTEycE83S1dwX1kzQWlxNlktazZySXNLTl9NSERqYWNKeGl6Ql…
Insider Sale: Chief Medical Officer of $ARTV Sells 8,222 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxON2ZlT1RscEc5dkZzaXlpTGRoeHA5YzVRS1VBMU01c3VteUhmNERCQzZSdUlieGszdGhFQm14azJHRUpfc1VMczR4V0pmVlBfV2RuVnQ0NkxFZDlwQmNUM3ZNLWVMamRRTEVGd3Qzem45Y1FpTTRDczc2YkZrZzlKYXVhWFR0YkhWNmJUc0…
Should I buy Artiva Biotherapeutics, Inc. (ARTV) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE1MZFlINzg4dmQzN1BlSDR4ZDdkNnMxNmlrN2x5THVuNXAzS2xPZnJjUWdXVk5iMnl0UmF6UExwQnB6NnVZekZiTHczc1NMS1dZZUFWanUxRXl2VTFvQkp6SWMwYkd0QzE4UlgyYQ?oc=5" target="_blank">Should I buy Artiva B…
ARTV — Frequently Asked Questions
What is the current share price of Artiva Biotherapeutics, Inc. (ARTV)?
As of 2026-09-19 21:16 PDT, Artiva Biotherapeutics, Inc. (ARTV) trades at $10.88 on NasdaqGM. Its 52-week range is $2.28 to $13.39.
What is the market capitalisation of ARTV?
Artiva Biotherapeutics, Inc. (ARTV) has a market capitalisation of $531.92M on NasdaqGM.
What is the P/E ratio of ARTV?
ARTV trades at a trailing price-to-earnings (P/E) ratio of -3.37. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.52.
What is the return on equity (ROE) of ARTV?
ARTV has a return on equity (ROE) of -36.58%. Its return on capital employed (ROCE) is -76.21%.
Is ARTV a good stock to buy?
This page provides a data-driven analysis of Artiva Biotherapeutics, Inc. (ARTV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.